Treatment with tirzepatide in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss and nearly 99% remained diabetes-free at 176 weeks

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

FDA Approves Lilly's Zepbound (Tirzepatide) for Chronic Weight Management

Eli Lilly reports successful Phase 3 study for weight loss drug, with 63% of participants losing at least 20% of body weight on highest dose.